The Team of Bioprocessing Technology Institute and Roche Pharma Research

The company A-Star (BTI) decided to
make a deal with the pharmaceutical
establishment Roche. Those wise em-
ployees certainly want to find and era-
dicate cancer. It has been on this plan-
et Earth too long.

Roche’s employees have the ability to
make the monoclanal antibody (mAbs)
therapeutics, which will give them more
ideas for great treatments. A-Star’s Bio-
processing Technology Institute has m-
embers of the staff that can discover n-
ovel antibody.

The company BTI came up with a fresh
mechanism that allows antibodies to ta-
rget and eliminate cancer cells directly.
The high levels of sugar on the cancer
cells’ surfaces tells them apart from r-
egular cells.

The mAbs notice the targets of sweet
stuff so they reveal actual identities of
cancer cells. The most commonly util-
ized antibodies only aim for the protei-
ns. The so novel mechanism of actio-
ns that the mAbs possess makes po-
res form on the cancer cell’s surfac-
es.

The swift actions will degrade those c-
ells and cause the cancer cells to die.
The top scientist and lead investigator
of the project is Dr. Andre Choo. Oth-
er scientists helped out & they work-
ed hard (They still do excel).

With their skill-sets, the team made a
wide pathway of mAbs for the most d-
eadliest cancers. In other words, BTI
plus Roche equals stronger tests put
in place and more of the effective tre-
atments created faster.

The treatments will be able to work w-
ith the current 1’s. Dr. Juan-Carlos Lo-
pez is the head of the Roche Pharma
Research & Early Development Aca-
demic Relations Collaborations. He k-
nows that the partnership is necessa-
ry. They will improve a lot.